Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors

Compound 10b3 (EC50 = 0.047 (wild-type) and 4.6 μM (mutant)) with dual structural conformations was designed via molecular hybridization, and could occupy the protein/solvent interface and the entrance channel of HIV-1 NNIBP simultaneously.